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ABSTRACT
Allergy has now become amongst the commonest disease in the world and the patients are increasing. There
have been significant improvements in our understanding of allergic disease and its management. However
there are still many unclear points in the precise mechanism of allergic diseases and therapy. Recent wide and
extensive investigations suggest that the underlying mechanism of allergic disease is closely related to the al-
lergic inflammation. The aim of this review is to offer a state-of-the-art description in our research concerning
the allergic inflammation from the immunopharmacological standpoint．
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INTRODUCTION
Research in the past decade has provided extensive
evidence regarding the manner of onset and therapy
for immuno-inflammatory diseases including allergic
asthma, allergic rhinitis, atopic dermatitis1-5 and some
autoimmune diseases. Bronchial asthma, a typical al-
lergic disease, has been described as involving sub-
chronic eosinophilic epithelial desquamative inflam-
mation of the airway. Allergic rhinitis and atopic der-
matitis are also inflammatory diseases , as their
names indicate. In other words, allergic inflammation
is the basic pathophysiology of allergic diseases and
is closely associated with their progression and exac-
erbation . Recent advances in immunological and
molecular-biological research have improved our un-
derstanding the mechanism of allergic inflammation
(Fig. 1 ). The focus has shifted from the overall body
to tissues, from tissues to cells , and from cells to
functional molecules and genes. However , the pre-
cise mechanism of allergic inflammation is still un-
clear. In this paper, an immunopharmacological ap-
proach to elucidating the mechanism of allergic in-
flammation will be described. Since our final purpose
is to develop a new remedy for allergic diseases, we
tried to study the role of inflammatory cells and mole-
cules in allergic reactions as a target for new thera-
peutic agents. While much effort has been paid to de-
veloping new anti-allergic drugs , complete under-
standing of the allergic disease process has yet to be
conquered. Notably , many problems remain to be
solved , including airway hyperresponsiveness and
airway wall remodeling in bronchial asthma, nasal ob-
struction in allergic rhinitis, and itching and eczema-
like symptoms in atopic dermatitis. All of these symp-
toms are intractable conditions. The development of
new therapeutic agents is necessary. This paper fo-
cuses on our research into the mechanism of allergic
inflammation, which is the basis of these intractable
conditions , and development of new therapeutic
agents．
As a first step, we created a mouse model that re-
flected some clinical allergic conditions. To study the
role of inflammatory cells in allergic diseases, mice
lacking a certain kinds of cells were used. Then, in or-
der to identify the functional molecules of allergic re-
actions, a comprehensive gene analysis and certain
gene-deficient mice were used. After the identifica-
tion of functional molecules, we studied the efficacy
of inhibitors of these functional molecules in experi-
mental allergic disease models. This paper does not
touch upon nasal obstruction in allergic rhinitis and
itching in atopic dermatitis, because, for the former,
antithromboxane agents and steroids are currently
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Fig. 1 The process of alergic inflammation
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Table 1 Comparison of alergic and non-alergic inflammation
Non-alergic inflammationAlergic InflammationItem
Primary; Infection Physicochemical stimuli
Secondary; Immunological stimulation
AntigenCause
Tissue cels, NeutrophilAPC, T cel, B cel, Mast cel, EosinophilCels
Flare, Fever, Sweling, Pain
Tissue Dysfunction, Remodeling
Flare, Sweling
Tissue Dysfunction
Remodeling
Pathology
Anti-inflammatory steroid
Non-steroidal anti-inflammatory drug
Gold, etc
Anti-inflammatory steroid
Anti-histamine, Anti-LT
Anti-TxA2, Mast cel stabilizer
Desensitization, etc
Pharmacology
APC: Antigen presenting cels　LT: Leukotriene　TxA2: Thromboxane A2
highly effective , and, for the latter , no sufficiently
good outcomes have been obtained．
ALLERGIC INFLAMMATION AND NON-
ALLERGIC INFLAMMATION
Table 1 shows a comparison between allergic inflam-
mation and non-allergic inflammation . There are
roughly two stages in allergic inflammation, the in-
duction phase due to an immunological mechanism
and the effector phase due to an inflammatory mecha-
nism (refer to Fig. 1). In the induction phase, the im-
munoglobulin or the effector T cell produced as the
result of activation of the immunological mechanism
works as a trigger of disease. In this stage, antigen-
specific immunoglobulin or effector T cells are de-
tected in the blood . In the immunological mecha-
nism , immunocompetent cells including antigen-
presenting cells, T cells and B cells play a role. When
antigen exposure occurs repeatedly , inflammatory
cells, such as mast cells and eosinophils, participate
in the activation of the immunological mechanism,
blurring the distinction between the induction stage
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Table 2 Summary of pathological changes in antigen-induced airway hyperesponsiveness (AHR) in mice
AHREoTh2 cykIgEMiceDefective Cel
＋＋＋＋＋＋＋＋Wild
－－－－Nu/nu−/−T cel
－＋＋＋＋＋＋W/WVMc
＋＋＋＋＋＋＋＋
W/WV
＋
BMMC
＋＋＋＋＋＋＋sIL-5RαEo
＋＋＋＋＋＋＋a-IL-5
＋＋: Moderate increase　＋: Slight increase　－: no change　Mc: mast cel
Cyk: Cytokine　Eo: Eosinophil
Table 3 Summary of pathological changes in antigen-induced airway hyperesponsiveness (AHR) in mice
AHREoTh2 CykIgE
MoleculeDefective
＋＋＋＋＋＋＋＋Wild
－＋－－IL-4Th2 Cyk
－－＋＋IL-13
－－－－NGF-p75Co-s
－＋＋＋＋＋5-LOLO
＋＋＋＋＋＋＋＋EP1PG
＋＋＋＋＋＋＋＋＋＋＋EP3
＋＋＋＋＋＋＋＋EP4
＋＋＋＋＋＋＋＋＋＋＋IP
－＋＋＋＋DP
－＋＋＋＋＋＋TP
＋＋＋: Marked increase　＋＋: Moderate increase　＋: Slight increase　－: no change
NGF: Nerve growth factor　LO: 5-Lipoxygenase　Cyk: Cytokine  Eo: Eosinophil 
Mice
and the effector stage. In order for a response to be
formed, many mediators, including cytokines and ad-
hesion molecules, must play roles in the respective
phases．
From a pathological standpoint, allergic inflamma-
tion does not always involve all of the five major char-
acteristics of non-allergic inflammation, flare, fever,
swelling, pain and tissue dysfunction. Fever and pain
appear only in special cases of allergic inflammation.
The inflammatory response in allergic inflammation
progresses in stages in the same order as in non-
allergic inflammation, namely, exudation, cellular in-
filtration and tissue repair. However, in the cellular in-
filtration stage , while neutrophils are dominant in
non-allergic inflammation, eosinophils are dominant
in allergic inflammation. In the tissue repair stage,
while granulation and rheumatic progressive changes
occur relatively frequently in non-allergic inflamma-
tion, this stage in allergic inflammation is character-
ized by tissue remodeling following exacerbation and
chronicity. In the tissue repair stage of either type of
inflammation, macrophage series cells play a leading
role by producing growth factors. In allergic inflam-
mation, in addition to macrophages, the mast cells,
eosinophils and epithelial cells work as modulators．
Pharmacologically, while the usefulness of steroi-
dal anti-inflammatory drugs is common to both types,
so-called non-steroidal anti-inflammatory drugs are ef-
fective for non-allergic inflammation but often ineffec-
tive for allergic inflammation．
As described above, allergic inflammation and non-
allergic inflammation resemble each other in some
points but differ in many others. However, in accor-
dance with the final objective of our research which is
the development of therapeutic agents for intractable
allergic symptoms, from cellular and molecular stand-
points we planned to elucidate the characteristics of
the mechanisms of inflammation, which from the ba-
sis of these intractable conditions．
THE MECHANISM UNDERLYING ALLERGIC
AIRWAY HYPERRESPONSIVENESS , AND
DEVELOPMENT OF THERAPEUTIC AGENTS
The mechanism of airway hyperresponsiveness , an
important symptom of bronchial asthma, remains un-
clear, even though many clinical and basic studies
have been conducted on the subject . 6-20 First , we
tried to produce a mouse model of airway hyperre-
sponsiveness due to an allergic mechanism.21,22 Mice
were immunized systemically , then made to inhale
antigen 3 times. Figure 2 shows the results of the air-
way hyperresponsiveness model. In this model, the
dose response curve for the contraction by acetyl-
choline in allergic mice shifted to the left and the area
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Fig. 2 Changes in airway hyperesponsiveness with acetylcholine, immunoglobulin levels in serum, the number of infiltrated 
cels in airway and cytokine levels in bronchial alveolar lavage fluid after repeated alergen provocation and treatment with 
prednisolone. Each value represents the mean ± SEM of 8―12 mice. S-Sal; Injection and inhalation of saline instead of alergen, 
S-OA; Immunization and inhalation of ovalbumin (alergen), Pred; Administration of 5 mg/kg prednisolone after immunization 
and inhalation of ovalbumin, **: P < 0.05, ***: P < 0.01.
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under the curve (AUC) increased when compared to
normal saline-treated mice. A high level of IgE pro-
duction and eosinophilic infiltration were observed in
allergic mice. The levels of Th2 cytokines such as in-
terleukin 4 (IL-4), IL-5 and IL-13, were elevated, while
the level of interferon gamma (IFN-γ ) , a Th1 cy-
tokine, was lowered in antigen exposed mice. The
above symptoms improved following administration
of prednisolone, suggesting that the model was use-
ful as a model for immuno-pharmacological studies.
In the next experiment, cells and molecules associ-
ated with the onset of hyperresponsiveness were in-
vestigated using the model with defective cells or de-
fective genes that coded molecules. Table 2 summa-
rizes findings in mice that were defective in specific
cells . 21-24 Results suggested that T cells and mast
cells played important roles in the onset of airway hy-
perresponsiveness, while eosinophil were not a major
player. In particular, the role of the mast cell was con-
firmed, because the airway hyperresponsiveness of
mast cell-defective mice recovered following the
transfer of cultured bone marrow-derived mast cells．
In molecular studies, changes in genes were ana-
lyzed comprehensively before and after the onset of
airway hyperresponsiveness. Although not all genes
have been fully analyzed, those encoding for cytoki-
nes, chemokines, their receptors, ion-channels, en-
zymes and others were altered significantly. Table 3
shows the results of the investigation employing cy-
tokine and arachidonate receptor gene-deficient
mice. The results suggest that the Th2 cytokines and
among lipid mediators including Leukotriene (LT),
prostaglandin D2(PGD2 )and thromboxane A2(TxA2 ),
played important roles in inducing airway hyperre-
sponsiveness in the model.25-29 The Th1 cytokines,
prostaglandin E2(PGE2 ) and I2(PGI2 ) worked as in-
hibitory factors against the onset of allergic inflamma-
tion. In particular, PGE2 seemed to express its inhibi-
tory action principally due to the interference of in-
flammatory cell activation through the EP3 receptor.
Results also demonstrated that prostaglandin I2 inhib-
ited the inclination from Th0 toward Th2 in T cells. Al-
lergic capillary permeability was markedly increased
in IP (PGI2 receptor) gene-defective mice compared
to wild mice. In T cells obtained from immunized IP-
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Fig. 3 Possible mechanism of alergic inflammation underlying airway hyper-
responsiveness. Mc; Mast cels, Eo; Eosinophils, Ep; Epithelial cels, SM; Smoo-
th muscle,  IP; Prostaglandin I2 receptor, EP; Prostaglandin E2 receptor, DP; 
Prostaglandin D2 receptor,  CRTh2; Chemoatract receptor homologous molecule 
expressed on Th2 cels, cysLT1; cytenyl leukotriene receptor 1, AHR; Airway hy-
peresponsiveness
B
cell Mc
Eo
T
cell
(IP)
Th1
PGI2
IgE
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PGE2
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Ep
SM
Antigen
Th2
AHR
Table 4 Summary of drug eficacy against antigen-induced airway hyperesponsiveness (AHR) in mice
AHREoTh2 CykIgE(No. of examined drugs)Drug
＋＋＋＋＋＋＋＋Wild
－－－ND(2)T cel immunosuppressor
＋＋＋＋－(1)anti-IL-4 antibody
＋＋＋＋＋＋＋(1)anti-IL-5 antibody
＋＋＋＋＋(2)IFN-γ (β)
＋＋＋＋＋＋＋＋(3)Cytokine inhibitors
＋＋＋＋＋＋＋＋(5)Mast cel stabilizer
＋＋＋＋＋＋＋＋(5)Anti-histamines
＋＋＋＋＋＋＋＋(2)PGI2 agonist
＋＋＋＋＋＋＋＋(1)EP3 agonist
＋＋＋＋＋(1)Anti-PGD2
＋―－＋―－＋―－＋＋(5)Anti-LT
＋―－＋＋＋＋＋＋(2)Anti-TxA2
＋―－＋＋＋＋＋(2)Anti PAF
＋＋＋＋＋＋＋(3)PDE inhibitor
＋＋＋＋―＋＋＋―＋＋(3)Eosinophil inhibitor
＋＋: Marked increase　＋: Slight increase　－: no change
Cyk: Cytokine　Eo: Eosinophil
defective mice, while the production of the Th2 cy-
tokine IL-4 increased following addition of antigen,
the production of IFN-γ, a Th1 cytokine, decreased
when compared to each production by T cells from
wild type mice. Consequently, it was thought that the
responsiveness in IP-defective mice inclined toward a
Th2 response. Figure 3 shows a schema of the aller-
gic inflammation underlying the onset of airway hy-
perresponsiveness, that is , the Th2 cells activated
upon antigen invasion stimulate B cells to produce
the IgE antibody under control of the Th1 cytokines.
The IgE antibody is fixed to mast cells through its FCε.
When the antigen invades again, mast cells are acti-
vated and produce many mediators including PGD2,
LT and chemokines. Chemokines gather inflamma-
tory cells such as eosinophils at the responsive locale,
amplifying allergic inflammation . However , it was
thought that mast cells are the leading player in air-
way hyperresponsiveness, while eosinophils are a mi-
nor player. The present results indicate that among
prostanoids possibly produced by mast cells, PGD2,
TxA2 and LT facilitate the onset of airway hyperre-
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Fig. 4 Time course studies on the changes of various parameters in 
airway wal remodeling in mice. BALF; Bronchial alveolar lavage fluid, 
TGF; Transforming growth factor
Response
Cells (BALF)
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sponsiveness. PGI2 and PGE2 control the progress of
an allergic inflammatory response through the IP re-
ceptor in T cells and the EP3 receptor in tissue inflam-
matory cells, respectively.
Next, efforts were made to find a new remedy for
airway hyperresponsiveness based on the above
mechanism of inflammation. The pharmacological ef-
fects on airway hyperresponsiveness were studied in
T cell immuno-suppressors , Th 2 cytokine depres-
sants, Th1 agonists, mast cell stabilizers, antihista-
mines and inhibitors for lipid mediators.30-37 Results
are summarized in Table 4. The drugs useful for
treating airway hyperresponsiveness were T cell im-
munosuppressors and agents affecting lipid media-
tors. Among the immunosuppressors, cyclosporine A
and tacrolimus hydrate, which act on T-cells, demon-
strated strong inhibitory actions against allergic air-
way inflammation and hyperresponsiveness . Cyclo-
phosphamide did not affect airway hyperresponsive-
ness, although the agent suppressed airway inflam-
mation. Th2 cytokine depressants and Th1 agonists
did not affect airway hyperresponsiveness, while they
were useful for suppression of airway inflammation.
Mast cell stabilizers, antihistamines and phosphodi-
esterase inhibitors had no effect on airway hyperre-
sponsiveness, although they partially suppressed air-
way inflammation. Cysteinyl LT, TxA2 and platelet ac-
tivating factor (PAF) inhibitors showed apparent in-
hibitory actions against airway hyperresponsiveness．
The above results demonstrated that T cell im-
munosuppressors and lipid mediator inhibitors were
effective in suppressing airway hyperresponsiveness.
These results suggest that airway hyperresponsive-
ness induced by ongoing inflammation could be con-
trolled only by the potent suppression of inflamma-
tion at either the initial stage or the final stage.
THE MECHANISM OF ALLERGIC INFLAM-
MATION AT THE BASIC LEVEL OF AIRWAY
WALL REMODELING AND DEVELOPMENT
OF THERAPEUTIC AGENTS
When airway allergic inflammation takes place re-
peatedly, tissue remodeling, that is, the reconstruc-
tion of tissues, occurs as a defense reaction against
injurious stimuli. The remodeling results in a chronic
narrowing of the airway lumen and decreased reactiv-
ity of airway smooth muscle relaxants, which are a
partial cause of asthmatic death. We attempted to elu-
cidate the mechanism of allergic inflammation at the
basic level of airway wall remodeling and develop-
ment of therapeutic agents. Many trials were carried
out to produce an airway wall remodeling model due
to an allergic mechanism.38-43 A suitable model was
obtained in mice by systemic immunization and fol-
lowing inhalation of allergen once a day for 3 weeks
before observation for 4 weeks. Results are shown in
Figure 4. During the period of allergen inhalation, the
number of inflammatory cells and the production of
Th2 cytokines increased. The production of TGF-β1
peaked 2 weeks after the initial inhalation of antigen.
Subepithelial fibrosis, one of the characteristics of air-
way wall remodeling, continued to be observed over
4 weeks after the discontinuation of allergen inhala-
tion, suggesting that the change was irreversible.
The roles of cells were investigated using the
above model . Table 5 shows results obtained from
mice that were genetically or artificially defective in
certain cells . In mice with defective T cells or de-
prived of CD4-positive T cells using anti-CD4 mono-
clonal antibody, epithelial hypertrophy, subepithelial
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Table 6 Summary of pathological changes in antigen-induced airway remodeling and hyperesponsiveness (AHR) in mice
AHRSEFHP
TGF-
β1
EP hyEo
Th1
Cyk
Th2
Cyk
IgE
MoleculeDefective
＋＋＋＋＋＋＋＋＋＋＋＋md＋＋＋＋Wild
＋＋＋＋＋＋－－－IL-4Th2 Cyk
－－－＋－－sd＋＋IL-13
＋＋＋＋＋＋＋＋＋＋＋md＋＋＋＋5-LO5-LO
＋＋＋＋＋＋＋＋＋＋＋＋md＋＋＋＋DPPG
＋＋＋＋＋＋＋＋＋＋＋＋＋＋＋＋＋md＋＋＋＋＋＋IP
＋＋＋＋＋＋＋＋＋＋＋＋md＋＋＋＋EP3
＋＋＋: Marked increase　＋＋: Moderate increase　＋: Slight increase
sd: Slight decrease　md: Moderate decrease　－: no change　Cyk:Cytokine
Eo: Eosinophilia　EP hy: Epithelial cel hyperplasia (Goblet cel)
HP: Hydroxyproline　SEF: Sub-epitherial fibrosis
Mice
Fig. 5 Potential mechanism of alergic inflammation underlying airway 
wal remodeling. Mc; Mast cels, Eo; Eosinophils,  Myofibro; Myofibroblast, 
Subepi; Subepithelial cels, Gob; Goblet cels, TGF; Transforming growth 
factor, AHR; Airway hyperesponsiveness
T
Cell
CD4+
B
cell
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Eo
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Airway Remodeling
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Table 5 Summary of pathological change in antigen-induced airway remodeling and hyperesponsiveness (AHR) in mice
AHRSEFHP
TGF-
β1
Ep hyEo
Th1
Cyk
Th2
Cyk
IgEMice
Defective
Cel
＋＋＋＋＋＋＋＋＋＋＋＋sd＋＋＋＋Wild
－－－－－－－－－nu/nuT cel
－－－－－－－－－CD4
＋＋＋＋＋＋＋＋＋＋＋＋sd＋＋＋＋CD8
＋＋＋＋＋＋＋＋＋＋sd＋＋＋＋W/WVMc
＋＋＋＋＋＋＋＋＋＋sd＋＋＋＋SI/SIV
＋＋＋＋＋＋＋＋＋＋＋＋sd＋＋＋＋
W/WV
＋
BMMC
±±±±±－sd＋＋＋＋IL-5RαKO
＋＋＋＋＋＋＋sd＋＋＋＋a-IL-5
＋＋: Moderate increase　＋: Slight increase　sd: Slight decrease　±: Trace　－: no change
Cyk: Cytokine　Eo: Eosinophilia　Ep hy: Epitherial cel hyperplasia (Goblet cel)
HP: Hydroxyproline　SEF: Sub-epitherial fibrosis
fibrosis and the production of TGF-β1, all indicators of
airway wall remodeling induced by the inhalation of
allergen were completely absent. In addition, airway
hyperresponsiveness did not occur in these mice. In
mice deficient in CD8-positive T cells, none of the re-
actions or responses to the allergen were affected. In
mice with defective mast cells, that is, WWV(c-kit
mutant) or SlSld (c-kit ligand mutant) mice, the ele-
Allergology International Vol 54, No2, 2005 www.js-allergol.gr.jp 257
Basic Research of Allergic Inflammation
Table 7 Summary of drug eficacy against antigen-induced airway remodeling and hyperesponsiveness (AHR) in mice
AHRSEFHP
TGF-
β1
EP 
Hyp
Eo
Th1
Cyk
Th2
Cyk
IgEDrug (No. of drugs)
＋＋＋＋＋＋＋＋＋＋＋＋md＋＋＋＋Wild
＋＋＋＋＋＋＋＋＋＋±±anti-IL-4 antibody (1)
＋＋＋＋＋＋＋md＋＋＋＋anti-IL-5 antibody (1)
＋＋＋＋＋＋＋＋＋＋＋＋md＋＋＋＋PGI2 agonist (2)
＋＋＋＋＋＋＋ND＋/＋＋md＋＋＋＋PGE2 (EP3) agonist (1)
＋＋ND＋＋＋＋ND＋ND＋＋＋＋LT antagonist (2)
＋＋＋＋＋＋＋＋＋＋＋＋md＋＋＋＋PDE inhibitors (2)
＋＋＋＋＋＋＋＋＋＋＋＋md＋＋＋＋MMP inhibitors (2)
＋ND＋＋＋＋ND＋＋＋CCR3 antagonist (1)
＋＋ND＋＋＋ND＋＋ND＋＋＋＋Pirprofen
＋＋ND＋＋＋＋ND＋＋ND＋＋＋＋Curucumin
＋＋: Moderate increase　＋: Slight increase　md: Moderate decrease　±: Trace
ND: Not done　LT: Leukotoriene  PDE: Phosphodiesterase　MMP: Matrix metaloprotease
Cyk: Cytokine　Eo: Eosinophilia　EP Hyp: Epithelial cel hyperplasia
HP: Hydroxyproline  SEF: Sub epithelial fibrosis
Fig. 6 Potential mechanism of alergic inflammation underlying contact hypersen-
sitivity as a model for atopic dermatitis. DC; Dendritic cels, MC; Mast cels 
DC T cell B cell
suppression
MC
Nerve
Itching
chemokine
Edema
Eczema
Epidermal Keratinocyte
Th1
Th2
TxA2
Enzyme,
Other 
mediators
Fig. 7 Elevation of serum total and DNP-specific IgE levels, and increases in infiltrated 
eosinophil count, IL-4 mRNA expression and numbers of scratching behavior caused by 
repeated painting with DNFB. Each column represents the mean ± SEM of 5 to 10 mice.
Total IgE
(µg/mL) (ng/mL)
Anti-DNP IgE
(cells/field)
Eosinophils
(IL-4/β-actin)
IL-4 mRNA
(/2 hours)
Scratching
6
5
4
3
2
1
0
20
15
10
5
0
80
60
40
20
0
1.5
1
0.5
0
800
600
400
200
0
N.D.N.D.
: non-treated : after the 9th DNFB　N.D. : not detected
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vation of hydoxyproline content and subepithelial fi-
brosis were suppressed slightly with no other pa-
rameter being affected . In mice having defective
eosinophils due to depletion of the IL-5 receptor -
chain gene and treatment with anti-IL-5 monoclonal
antibody, immunological responses were not affected
but epithelial cell hypertrophy and subepithelial cell
fibrosis were dramatically suppressed．
The above results suggested that CD4-positive T
cells and eosinophils were the leading player in the
onset of airway wall remodeling and that mast cells
are associated with only part of the changes．
Gene changes in the model at the onset were ana-
lyzed comprehensively . Although results have not
been fully analyzed, changes occurred in chemoki-
nes , enzymes such as matrix metalloprotease and
many kinases , and cytokines . Since more than 50
genes changed significantly, further studies concern-
ing the relationship among each gene seemed to be
necessary. As in the studies on the airway hyperre-
sponsiveness model, the roles of candidate molecules
were investigated using mice defective in genes re-
lated to cytokines and prostanoids and the neutraliz-
ing antibodies of cytokines. The results are summa-
rized in Table 6. In IL-4 gene-deficient mice , the
changes of airway wall remodeling were slight. In the
IL-13 gene-deficient mice, no change in airway wall
remodeling occurred , suggesting that the role of
IL-13 was slightly greater than that of IL-4. Lipid me-
diators, which played the major roles in airway hyper-
responsiveness, seemed to participate little in the on-
set of airway remodeling. In IP gene-deficient mice,
some parameters of airway remodeling including IgE
production, Th2 cytokine levels, eosinophilia, epithe-
lial hypertrophy, subepithelial fibrosis and TGF-β pro-
duction were improved. Studies using the neutraliz-
ing antibody of TGF-β1 demonstrated the possibility
of a dual role of the cytokine in the process of airway
wall remodeling. TGF-β1 played a role in epithelial fi-
brosis as an inducing factor and in the alteration of
epithelial cells to goblet cells as an inhibitory factor.
The above results can be depicted in a schematic dia-
gram for airway remodeling shown in Figure 5. CD4-
positive T cells and eosinophils were the leading play-
ers in the remodeling, IL-13 was the facilitator of the
onset , and TGF-β1 worked both in facilitation and
suppression. PGI2 played a role in the suppression of
T cell activation. In addition, Th2 cytokines from T
cells acted on the airway wall directly to promote the
remodeling.
Therapeutic agents useful in airway wall remodel-
ing were investigated using this model. As shown in
Table 7, of the neutralizing antibodies of cytokines,
anti- IL-5 antibody had a moderate suppressive action
in the development of epithelial cell hyperplasia and
subepithelial fibrosis . Among the drugs examined ,
the strongest was a CCR3 inhibitor, which is a migra-
tion factor for eosinophils . Pirfenidone and cur-
cumine, which suppress the fibrosis of other organs,
did not have apparent effects on airway wall remodel-
ing．
THE MECHANISM OF ALLERGIC INFLAM-
MATION AT THE BASIC LEVEL OF THE ON-
SET OF ECZEMA-LIKE SYMPTOMS IN THE
ATOPIC DERMATITIS MODEL AND THERA-
PEUTIC AGENTS
Atopic dermatitis is an intractable disease with severe
itching and recurrent eczema-like lesions. By apply-
ing allergens repeatedly on the skin, a mouse model
for atopic dermatitis was created in which elevations
of serum IgE levels , expression of Th 1 cytokine
mRNA at lesions, expression of Th2 cytokine mRNA
at associated lymph nodes and severe scratching be-
havior were observed (Fig . 6 ) . Using this model ,
cells and molecules necessary for the onset were in-
vestigated.44-52 T cells, specifically Th2 cells, played
an important role as an exacerbating factor. From the
data for mice deficient in a certain cells, mast cells
and eosinophil seemed to play a minor role in both
the onset and development of dermatitis. In order to
investigate the molecular pathology, gene expression
was studied comprehensively at the sites of allergic
reaction and at normal sites. Studies employing gene-
deficient mice indicated the importance of molecules
produced by keratinocytes and Th2 cells. Based on
the results from the experiments in mice, the mecha-
nism of allergic inflammation underlying atopic der-
matitis is hypothesized in Figure 7. As shown in Fig-
ure 7, TxA2 plays a suppressive role in the cognitive
recognition process between dendritic cells and T
cells.53 Th1 and Th2 were activated simultaneously .
While Th2 worked as an inducer, Th1 worked as an
inducer at lesions and an inhibitor of Th2 at other
sites . Fucosyltransferase and protease activated re-
ceptor 2, which are thought to be appeared in kerati-
nocytes, seemed to play roles in the onset.
Therapeutic agents for atopic dermatitis were in-
vestigated using this model. Drugs demonstrated to
be effective so far include glucocorticoid and a T cell
immuno-suppressant, tacrolimus hydrate. Most of the
anti-allergic drugs were found to be ineffective. More
studies are planned to investigate the actions of other
drugs possessing different mechanisms．
The conclusions described above shed light on the
mechanisms of allergic inflammation underlying
many disease symptoms and on the ideas for the de-
velopment of anti-allergic drugs. The mechanism of
allergic inflammation was studied principally using
comprehensive gene analysis, gene defective mice,
and neutralizing antibody with specific neutralizing
activity or soluble receptor obtained in genetic engi-
neering. It can be inferred that local gene expression
and control will be important methods used in future
studies. New anti-allergic drugs will target the inhibi-
tion of various molecules such as IL-13 and CCR3. At
Allergology International Vol 54, No2, 2005 www.js-allergol.gr.jp 259
Basic Research of Allergic Inflammation
the same time , order-made treatments using cur-
rently available drugs, that is, treatment suited to in-
dividual patients, should be actively sought. Great fu-
ture advancements in this field can be anticipated．
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